CAR-NK Cell Therapy Trial for HER2+ Breast Cancer
Summary
ClinicalTrials.gov registered a Phase I/II clinical trial (NCT07510802) evaluating CAR-NK cell therapy for HER2+ breast cancer. The trial is sponsored by a Beijing-based biotechnology company. This registry entry provides public disclosure of ongoing research but does not establish new regulatory obligations.
What changed
Study NCT07510802 documents a CAR-NK cell therapy investigation for HER2-positive breast cancer on the ClinicalTrials.gov registry. The registration includes sponsor information, trial phase, and therapeutic focus but provides limited procedural detail in this content excerpt.
Clinical investigators and sponsors should note this early-phase oncology trial for potential referral or enrollment purposes. No compliance actions are required from this registry entry alone. Sponsors of applicable clinical trials should ensure ongoing compliance with 42 CFR Part 11 registration and updates.
Archived snapshot
Apr 6, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.